Diana Giannarelli
Sapienza University of Rome
645 Papers
3.6K Citations
Diana Giannarelli is an academic researcher from Sapienza University of Rome. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 60, co-authored 544 publications. Previous affiliations of Diana Giannarelli include Università Campus Bio-Medico & University of Turin.
Chat about Author
Papers
Systematic Pelvic Lymphadenectomy vs No Lymphadenectomy in Early-Stage Endometrial Carcinoma: Randomized Clinical Trial
Pierluigi Benedetti Panici,Stefano Basile,Francesco Maneschi,Andrea Lissoni,Mauro Signorelli,Giovanni Scambia,Roberto Angioli,Saverio Tateo,Giorgia Mangili,Dionyssios Katsaros,Gaetano Garozzo,Elio Campagnutta,Nicoletta Donadello,Stefano Greggi,Mauro Melpignano,Francesco Raspagliesi,Nicola Ragni,Gennaro Cormio,Roberto Grassi,Massimo Franchi,Diana Giannarelli,Roldano Fossati,Valter Torri,M. Amoroso,Clara Crocè,Costantino Mangioni +25 more
TL;DR: Although systematic pelvic lymphadenectomy statistically significantly improved surgical staging, it did not improve disease-free or overall survival.
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.
Luisa Carbognin,Sara Pilotto,Michele Milella,Vanja Vaccaro,Matteo Brunelli,Anna Caliò,Federica Cuppone,Isabella Sperduti,Diana Giannarelli,Marco Chilosi,Vincenzo Bronte,Aldo Scarpa,Emilio Bria,Giampaolo Tortora +13 more
TL;DR: Overall, the three antibodies provide a significant differential effect in terms of activity according to PD-L1 expression on tumor cells, which seems to be more robust for anti-PD-1 antibody (nivolumab and pembrolizumab), and in the context of advanced melanoma and NSCLC.
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
Mariaelena Capone,Diana Giannarelli,Domenico Mallardo,Gabriele Madonna,Lucia Festino,Antonio M. Grimaldi,Vito Vanella,Ester Simeone,Miriam Paone,Giuseppe Palmieri,Ernesta Cavalcanti,Corrado Caracò,Paolo A. Ascierto +12 more
TL;DR: Both Neutrophil-to-lymphocyte ratio (NLR) and derived (d) NLR were associated with improved survival when baseline levels were lower than cut-off values, and NLR and dNLR are simple, inexpensive and readily available biomarkers that could be used to help predict response to immunotherapy in patients with advanced melanoma.
419
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.
Pier Francesco Ferrucci,P.A. Ascierto,Jacopo Pigozzo,M. Del Vecchio,Michele Maio,G. C.Antonini Cappellini,Massimo Guidoboni,Paola Queirolo,Paola Savoia,Mario Mandalà,Ester Simeone,Sara Valpione,Maresa Altomonte,Francesco Spagnolo,Emilia Cocorocchio,Sara Gandini,Diana Giannarelli,Chiara Martinoli +17 more
TL;DR: It is suggested that a neutrophil-based index may help risk-group stratification and assist disease-management strategies and the potential predictive value of this index for response to ipilimumab should be investigated in randomized clinical trials.
372
Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy.
Antonio M. Grimaldi,Ester Simeone,Diana Giannarelli,Paolo Muto,Sara Falivene,Valentina Borzillo,Francesca Maria Giugliano,Fabio Sandomenico,Antonella Petrillo,Marcello Curvietto,Assunta Esposito,Miriam Paone,Marco Palla,Giuseppe Palmieri,Corrado Caracò,Gennaro Ciliberto,Nicola Mozzillo,Paolo A. Ascierto +17 more
TL;DR: RT after ipilimumab may lead to abscopal responses in some patients with advanced melanoma correlating with prolonged OS, and it is suggested that local responses to RT may be predictive of abscopy responses.
369